BERINGEA SUPPORTS ALL IN ONE MEDICAL’S TRANSATLANTIC EXPANSION WITH FURTHER INVESTMENT OF £5.5M
25 Aug 2016
Further funding for leading medtech business aiming to prevent infections spreading with new textiles
Venture and growth investor Beringea, has invested a further £5.5m in All in One Medical, the market leader in creating disposable healthcare textiles which actively destroy harmful pathogens.
The funding for the British medical manufacturing business comes from Beringea’s UK and US offices and will be used to support All in One Medical’s international growth plans, notably its expansion into the U.S. marketplace with a manufacturing plant in Michigan. Other plans include growth into the UK, Europe and Australia and further developing its product range through numerous new applications.
Healthcare-associated infections have become a global public health issue and have a significant impact on healthcare delivery. All in One Medical offers a range of high quality and highly effective disposable and biocidal products that are able to help reduce the rate of infection and save lives.
Beringea first invested in All in One Medical in February 2014 with £3m to support the growth of the Wolverhampton (UK) manufacturing plant and assist the company in its acquisition of Fantex, a leading manufacturer of antimicrobial biocide.
Malcolm Moss, Founding Partner, Beringea UK, said: “Since first backing the All in One Medical team in February 2014, we’ve been impressed by the company’s growth trajectory, establishing the business as market leaders in manufacturing and distributing antimicrobial products. All in One Medical’s products tackle an important issue facing hospitals around the world, and today’s funding marks the next step in infection prevention.”
Charles Rothstein, Founding Partner, Beringea US., said: “The opening of a manufacturing plant in Michigan is great news for both the business and our state, as it brings new jobs to the region. Fast-growing companies like All in One Medical reap the benefits of having a transatlantic investor as they enter new countries and navigate new markets, and the global Beringea team is excited to support their growth plans.”
Hal Zaima, North American General Manager, All in One Medical “We are very excited about launching All in One Medical in the US and are delighted to be setting up a manufacturing base in Michigan. We have put together a very strong management team and look forward to working with Beringea as we meet the challenges ahead”
Matthew Wheeler, European General Manager, All in One Medical, said: “We’re proud to be partnering with both transatlantic Beringea teams today. As a business we continue to grow, develop and launch new products, and this funding will allow us to continue our international expansion into Europe and Australia, as well as the major development in the US.”
Beringea is a venture and growth capital investor in high growth businesses, with £450m ($600m) under management and 60 portfolio companies. Based in London, UK, and Michigan, U.S., Beringea is able to invest between £1m - £20m into businesses looking for a supportive growth partner.
With £170 million managed from London, and over 40 portfolio businesses, Beringea’s UK team manages one of the country's biggest evergreen venture and growth capital funds. The team of highly experienced investors has a great track record across a variety of sectors, and has demonstrated a consistent ability to identify winning companies and outstanding management teams.
About All in One Medical
All in One Medical is the industry leading manufacturer and supplier of antimicrobial disposable curtains, roller blinds and other innovative antimicrobial cleaning products for the healthcare industry. Able to kill up to 99.999% of microbes in under one minute, including MRSA and Norovirus, our pioneering antimicrobial, Fantex TM, helps to prevent healthcare associated infections in hospitals and other healthcare environments throughout the world. For further information, please visit www.allinonemedical.com.